Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies for liver diseases and viral infections. Its core programs target chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections. The company’s pipeline includes pevifoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections, alongside preclinical oligonucleotide programs. Aligos is still pre-commercial, so its business is centered on research, clinical development, external funding, and potential future partnerships rather than product sales.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLead therapeutic programs in HBV, MASH/obesity, and coronavirus infections that are being advanced through preclinical and clinical development.
siRNA and ASO-based discovery and development capabilities used to create liver-targeted antiviral and metabolic disease therapies.
Proprietary BNA and GalNAc chemistries licensed to improve potency, pharmacokinetics, and liver delivery.
Revenue from research and development services and prior collaboration arrangements while the pipeline remains pre-commercial.
Customers
Aligos does not sell approved medicines, so its current revenue comes from collaboration agreements and third-party research and development contracts rather than end-market product customers. Its primary economic counterparties are pharmaceutical collaborators, government funders, and research partners that support specific programs such as coronavirus development. The eventual commercial customers, if products are approved, would be physicians, hospitals, and specialty prescribers treating liver disease and viral infections. In the near term, the company’s customer base is therefore concentrated in funding partners and development collaborators that help finance and de-risk its pipeline.
Pharma and biotech partners that provide upfront, milestone, or shared-development funding for pipeline programs.
NIH, NIAID, and related agencies funding coronavirus studies and other externally supported research.
Third parties purchasing R&D services that generate contract revenue while the company remains pre-commercial.
Hepatologists, infectious disease specialists, and treatment centers that would prescribe approved therapies if development succeeds.
Strategy
Aligos’ strategy is to advance a small number of differentiated, potentially best-in-class drug candidates in liver disease and viral infections. The company is prioritizing chronic HBV, MASH/obesity, and coronavirus programs where it believes its chemistry and delivery platform can create clinical differentiation. It is also using external funding, government grants, and collaborations to reduce the capital burden of development, especially for ALG-097558. Longer term, the company may commercialize selectively on its own or partner with larger pharmaceutical companies to expand reach and reduce execution risk.
HBV is a core value driver and a major unmet medical need where clinical success could validate the platform.
This expands the pipeline into a large metabolic disease market and diversifies the company beyond antivirals.
External funding lowers cash burn and supports continued development of ALG-097558 without relying solely on equity capital.
Collaborations can provide capital, development expertise, and commercialization access for a pre-commercial biotech.
Geography
Aligos is headquartered in the United States and its business is primarily managed from there. The company’s current development footprint is global in nature because its clinical and nonclinical work can involve U.S. government funding, U.K.-supported platform trials, and external contractors. Its coronavirus program has been supported by NIH/NIAID funding in the United States and by the AGILE platform trial in the United Kingdom. Because the company is pre-commercial, geography matters more for where research is funded and conducted than for where products are sold.
Risks
Aligos faces the classic risks of a clinical-stage biotech: no approved products, no product sales, and a long path to proving safety and efficacy in humans. The company has a limited operating history and expects continued losses, so its ability to fund development depends on future capital raises, collaborations, or external grants. Its pipeline is concentrated in a few programs, which makes setbacks in HBV, MASH, or coronavirus development especially damaging. More broadly, it also faces competition from better-funded biopharma companies, regulatory uncertainty, and the possibility that public funding or trial support for coronavirus programs could change.
- Clinical development failureImpact: CriticalLikelihood: High
The company’s value depends on proving safety and efficacy for a small number of drug candidates.
Exposure - Need for additional capitalImpact: HighLikelihood: High
The company expects continued losses and has stated that existing resources may not be sufficient beyond the near term.
Exposure: Corporate funding and pipeline advancement
- Dependence on external funding and collaborationsImpact: HighLikelihood: High
Coronavirus development is partially funded by NIH/NIAID and platform-trial support, which may not continue.
Exposure: ALG-097558
- Competition from larger biopharma companiesImpact: HighLikelihood: Medium
Competitors may reach approval faster, have stronger IP positions, or offer better efficacy and safety.
Exposure - Regulatory and reimbursement uncertaintyImpact: MediumLikelihood: High
Even successful candidates must clear lengthy approval pathways and future pricing/reimbursement hurdles.
Exposure: Future commercialization
Accounting
Judgemental itemsManagement must estimate unbilled CRO, clinical, and manufacturing costs, which can shift reported expenses between periods.
Impact: Affects operating expenses and period-to-period comparability
Revenue is recognized over time as costs are incurred, making timing dependent on project progress and contract terms.
Impact: Can create lumpy quarterly revenue and margin patterns
Changes in warrant valuation can materially affect net income or loss without changing cash operating performance.
Impact: Can distort bottom-line results and EPS-like metrics
The company’s cash runway and need for additional funding are central to financial statement interpretation.
Impact: Important for liquidity analysis and financing risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Alumis Inc
ALMS · Pharmaceutical Preparations
Agios Pharmaceuticals, Inc
AGIO · Pharmaceutical Preparations
BioVie Inc
BIVIW · Pharmaceutical Preparations
Eledon Pharmaceuticals, Inc.
ELDN · Pharmaceutical Preparations
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Elicio Therapeutics, Inc.
ELTX · Pharmaceutical Preparations
Last updated: 24/09/2026